SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Barclays Downgrades Siemens Energy as Valuation Seen Near Peak 
China 618 Smartphone Sales Drop 13% as Higher Prices Hurt Demand, Huawei Gains Market Share 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
TetherMax Rebranding Highlights Official Exchange Partnerships and Transparent Operations 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Meta Says States Seek $1.4 Trillion in Penalties Over Teen Social Media Addiction Lawsuit 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Shell Raises Q2 Upstream Outlook, Flags Qatar Gas Hit as Shares Rise 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
NEW YORK, May 08, 2018 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Myriad Genetics, Inc. (NASDAQ:MYGN) who purchased shares between August 13, 2014 and March 12, 2018. The action, which was filed in the United States District Court for the District of Utah, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (i) Myriad was submitting false or otherwise improper claims for payment under Medicare and Medicaid for the Company’s hereditary cancer testing; (ii) the foregoing conduct would foreseeably subject Myriad to heightened regulatory scrutiny and/or enforcement action; (iii) Myriad’s revenues from its hereditary cancer testing were in part the product of improper conduct and unlikely to be sustainable; and (iv) as a result, Myriad’s public statements were materially false and misleading at all relevant times. On March 12, 2018, Myriad Genetics filed an 8-K with the United States Securities and Exchange Commission disclosing the receipt of a subpoena from the Department of Health and Human Services concerning “an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid.”
Shareholders have until June 19, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-c/myriad-genetics-inc?wire=3.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
